Clinical Outcomes in Patients With Acute Pulmonary Embolism Undergoing Ultrasound-Assisted Catheter-Directed Thrombolysis.
Dominik F Draxler, Judith Karen Johannes, Masaaki Nakase...
https://pubmed.ncbi.nlm.nih.gov/40281654Actively Recruiting
All Genders
ID04355975
Clinical Outcomes After Acute Pulmonary Embolism - The Bern Acute Pulmonary Embolism Registry
Led by Insel Gruppe AG, University Hospital Bern · Updated on 2022-12-15
800
Participants Needed
2
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are collecting data to study the safety and effectiveness of treatments for patients with pulmonary embolism (PE). This study focuses on treatments decided by a multi-disciplinary pulmonary embolism response team (PERT) and aims to improve treatment decisions, hospital procedures, and methods for PE care. It includes both past patients and those treated after May 2020. The study gathers information on various advanced treatments such as systemic thrombolysis, catheter-directed thrombolysis, and surgical removal of blood clots (embolectomy). It includes retrospective data from patients treated between 2001 and April 2020 and prospective data from patients treated after May 2020. The study records treatments and health outcomes related to acute and chronic PE. Participants will have their medical treatments and results reviewed, including any complications during procedures and any recurrence of blood clots up to five years later. Respiratory function and the development of chronic lung-related high blood pressure will also be monitored. The main outcome measured is death occurring within 30 days in the hospital. Participants are followed over time to understand long-term effects and safety.
CONDITIONS
Brief Title
Clinical Outcomes After Acute Pulmonary Embolism
Who Can Participate
All Genders
Eligibility Criteria
You may qualify if you...
- Consecutive patients with pulmonary embolism who are treated based on the decision of the pulmonary embolism response team (PERT).
- Must provide written informed consent.
You will not qualify if you...
- High likelihood that the patient will not follow the study's follow-up requirements.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Varies based on treatment modality and clinical course
Participants receive treatment for acute pulmonary embolism, which may include medical therapy, systemic lysis, interventional therapy, or surgical embolectomy based on the pulmonary embolism response team decisions.
Treatment occurs as part of routine healthcare; visit schedules vary accordingly
Long-term Monitoring
Duration - Up to 5 years
Participants are monitored for outcomes such as recurrent venous thromboembolism, respiratory and functional status, and development of chronic thromboembolic pulmonary hypertension for up to 5 years after treatment.
Follow-up visits as scheduled for up to 5 years
Trial Site Locations
Total: 2 locations
1
University Hospital Bern - Inselspital
Bern, Canton of Bern, Switzerland, 3010
Actively Recruiting
2
University Hospital Bern
Bern, Switzerland, 3010
Actively Recruiting
Loading map...
Research Team
S
Stefan Stortecky, MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here